Well Researched

Tesofensine

GLP & Metabolic · ['NS2330', 'TE']

Tesofensine is an investigational small-molecule triple monoamine (serotonin, noradrenaline, dopamine) reuptake inhibitor studied in clinical trials for metabolic and body-weight endpoints.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.

Molecular Formula

C17H23Cl2NO

Molecular Weight

328.3 g/mol

PubChem

CID 11370864 ↗

Research Level

Well Researched

Browse the store →

Tesofensine (development code NS2330) is an investigational small molecule, not a peptide, characterized as an inhibitor of the presynaptic reuptake of three monoamine neurotransmitters: serotonin, noradrenaline (norepinephrine), and dopamine [1]. It was originally investigated in neurological research contexts before metabolic endpoints became a focus [2].

The compound has been evaluated in randomized clinical trials examining body-weight and appetite-related endpoints in adult participants [2]. As an investigational agent it has not received general marketing authorization at the time of writing.

Because of its distinct small-molecule mechanism, tesofensine is often studied and referenced alongside peptide metabolic agents for comparison rather than as a member of the peptide class.

Tesofensine is described in the literature as a triple monoamine reuptake inhibitor, blocking the transporters that clear serotonin, noradrenaline, and dopamine from the synaptic cleft, thereby increasing their availability in central pathways studied in relation to appetite regulation [1].

Reported central-nervous-system and appetite-related effects are presented strictly as findings from cited preclinical and clinical studies, not as outcomes for any individual reader.

Triple monoamine (serotonin/noradrenaline/dopamine) reuptake inhibition pharmacology [1]
Body-weight and appetite endpoints in randomized clinical trials in adults [2]
Neurological research contexts including early Parkinson's and cognitive studies [1]
Cardiovascular and blood-pressure parameters monitored as safety endpoints in trials [2]
Dopaminergic signaling and reward-pathway studies in preclinical models [1]

📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

Phase 2 randomized trial (adults with obesity): A 24-week randomized, double-blind, placebo-controlled trial evaluated tesofensine across dose groups in adult participants with obesity, reporting change in body weight and safety endpoints including blood pressure and heart rate versus placebo [2]. Reported for scientific reference only.

Preclinical monoamine pharmacology: In vitro transporter-binding and animal studies characterized the compound's inhibition of serotonin, noradrenaline, and dopamine reuptake and associated appetite-related behavior [1].

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

Monoamine oxidase inhibitors (MAOIs)Caution

Combined monoaminergic activity is a recognized pharmacology consideration in the literature.

SSRIs / SNRIsCaution

Overlapping serotonin/noradrenaline reuptake mechanisms relevant to study design.

Sympathomimetic stimulantsCaution

Shared catecholaminergic pathways noted in cardiovascular safety monitoring.

GLP-1 receptor agonistsNeutral

Distinct mechanism; sometimes compared in metabolic research.

Is tesofensine a peptide?

No. It is a small-molecule triple monoamine reuptake inhibitor, referenced here alongside metabolic peptides for comparison [1].

What does tesofensine inhibit?

Published studies describe reuptake inhibition of serotonin, noradrenaline, and dopamine [1].

What have clinical trials measured?

A randomized phase 2 trial reported body-weight change and safety endpoints in adults with obesity [2].

Is tesofensine approved?

It is described as investigational and has not received general marketing authorization at the time of writing [2].

Can I take this product?

No. It is sold strictly for laboratory research use only and is not intended for human or veterinary use, nor to diagnose, treat, cure, or prevent any disease.

Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.